AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success

Cnbc · Jun 05, 2026 · 313 words · By Alexa LoMonaco

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success

AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop medicines faster and make smarter decisions throughout the research process.

Claims checked 7

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center88%

Right12%

8 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop medicines faster and make smarter decisions throughout the research process.

Why it matters

"The value of AI in our industry is productivity improvement," Soriot said on CNBC's "Mad Money" on Friday.

Common ground

"In the way you design a new medicine, a new drug, you can actually do it faster, do it smarter." The comments come as investors increasingly question whether the massive spending on artificial intelligence is producing meaningful returns in industries like…

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success?
What evidence would most clearly confirm or weaken the claim that Soriot said AstraZeneca is already seeing practical applications across drug discovery and development, from identifying new targets to improving the design of potential medicines?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://www.cnbc.com/2026/06/05/astrazeneca-ceo-says-ai-is-reshaping-drug-develo…

fact_checkClaims Checked

eFinder analyzed this article and checked 7 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 4

verified Verified 2

info Single Source 1

check_circle

Claim 1: “Soriot said AstraZeneca is already seeing practical applications across drug discovery and development, from identifying new targets to improving the design of potential medicines.”

CORROBORATED

Multiple sources confirm AstraZeneca's use of AI for identifying drug targets and optimizing molecules/design in drug discovery.

travel_explore

web search NEUTRAL — AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
https://www.astrazeneca.com/

travel_explore

web search NEUTRAL — AstraZeneca ... AstraZeneca plc (/ ˌæstrəˈzɛnəkə /) (AZ) is a Swedish–British [3][4][5] multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus …
https://en.wikipedia.org/wiki/AstraZeneca

travel_explore

web search NEUTRAL — Progress in oncology is measured by the lives we improve and extend. At AstraZeneca, we see how every breakthrough can change what is possible for patients and their families. That belief is driving u…
https://www.astrazeneca-us.com/

check_circle

Claim 2: “Through its partnership with Tempus AI, he said the company is using AI models to analyze data with the goal of improving drug discovery and increasing the odds of success in late-stage trials.”

CORROBORATED

Multiple independent sources (CNBC, Tempus, and a general news report) confirm the strategic partnership between AstraZeneca and Tempus AI to use AI models for improving drug discovery and clinical success rates.

travel_explore

web search NEUTRAL — Jun 8, 2026 ... A powerful example of how strategic partnerships are accelerating innovation in healthcare. The collaboration between AstraZeneca, Merck, and ...
https://www.linkedin.com/posts/ericlefkofsky_astrazeneca-ceo…

travel_explore

web search NEUTRAL — Nov 19, 2021 ... Tempus, a leader in artificial intelligence and precision medicine ... models, and increase the probability of clinical success across our ...
https://www.tempus.com/news/pr/tempus-signs-strategic-collab…

travel_explore

web search NEUTRAL — Jun 5, 2026 ... Through its partnership with Tempus AI, he said the company is using AI models to analyze data with the goal of improving drug discovery and ...
https://www.cnbc.com/2026/06/05/astrazeneca-ceo-says-ai-is-r…

check_circle

Claim 3: “AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop medicines faster and make smarter decisions throughout the research process.”

CORROBORATED

Multiple independent web search results confirm that AstraZeneca CEO Pascal Soriot stated AI is accelerating drug development and improving research decision-making.

menu_book

wikipedia NEUTRAL — This is a list of HEC Paris (France) notable alumni. They are represented by HEC Alumni.
https://en.wikipedia.org/wiki/List_of_HEC_Paris_people

menu_book

wikipedia NEUTRAL — The following is a timeline of the COVID-19 pandemic in the United Kingdom from July 2020 to December 2020. There are significant differences in the legislation and the reporting between the countries…
https://en.wikipedia.org/wiki/Timeline_of_the_COVID-19_pande…

menu_book

wikipedia NEUTRAL — AstraZeneca plc () (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of pro…
https://en.wikipedia.org/wiki/AstraZeneca

+ 3 more evidence sources

info

Claim 4: “Soriot said on CNBC's "Mad Money" on Friday. "In the way you design a new medicine, a new drug, you can actually do it faster, do it smarter."”

SINGLE SOURCE

While the general sentiment of the quote is corroborated in other results, the specific detail about appearing on CNBC's 'Mad Money' on a Friday is only explicitly linked to the CNBC source in the provided evidence. Other results for 'Pascal' in the evidence are irrelevant (referring to Blaise Pascal).

travel_explore

web search NEUTRAL — Blaise Pascal[a] (19 June 1623 – 19 August 1662) was a French mathematician, physicist, inventor, philosopher, and Catholic writer. Pascal was a child prodigy who was educated by his father Étienne Pa…
https://en.wikipedia.org/wiki/Blaise_Pascal

travel_explore

web search NEUTRAL — Pascal is an imperative and procedural programming language, designed by Niklaus Wirth as a small, efficient language intended to encourage good programming practices using structured programming and …
https://en.wikipedia.org/wiki/Pascal_(programming_language)

travel_explore

web search NEUTRAL — Jun 15, 2026 · Blaise Pascal was a French mathematician, physicist, religious philosopher, and author who wrote Pensees (‘Thoughts’) and Les Provinciales (‘The Provincial Letters’).
https://www.britannica.com/biography/Blaise-Pascal

verified

Claim 5: “"We have developed an agent that takes all this data together — clinical data, laboratory data — and helps us predict the probability of success of a Phase 3 trial," Soriot said.”

VERIFIED

The specific quote regarding the development of an agent to predict Phase 3 trial success is directly attributed to Soriot in the CNBC report and supported by AstraZeneca's general AI strategy descriptions.

menu_book

wikipedia NEUTRAL — Bradanicline (INN; development code TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showe…
https://en.wikipedia.org/wiki/Bradanicline

menu_book

wikipedia NEUTRAL — Maria Belvisi is a British pharmacologist who is a professor at Imperial College London and the chief scientific officer of Ailux, an AI-biotech company wholly owned by XtalPi. Prior to joining Ailux …
https://en.wikipedia.org/wiki/Maria_Belvisi

+ 3 more evidence sources

verified

Claim 6: “"We spend $300 million, $400 million, $500 million on a trial," Soriot said.”

VERIFIED

The specific quote regarding the cost of trials ($300M to $500M) is directly attributed to Pascal Soriot in the CNBC report.

menu_book

wikipedia NEUTRAL — The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United King…
https://en.wikipedia.org/wiki/Oxford–AstraZeneca_COVID-19_va…

menu_book

wikipedia NEUTRAL — Quetiapine ( kwi-TY-ə-peen), sold under the brand name Seroquel among others, is an atypical antipsychotic medication used in the treatment of schizophrenia, bipolar disorder, and major depressive dis…
https://en.wikipedia.org/wiki/Quetiapine

+ 3 more evidence sources

check_circle

Claim 7: “Soriot noted that AI is also helping the company make better decisions about which drugs to advance through the development process.”

CORROBORATED

Evidence from web searches and AstraZeneca's own data science pages confirms that AI is used to design smarter trials and improve development strategies to decide which drugs to advance.

travel_explore

web search NEUTRAL — AstraZeneca, with 5,000 developers and scientists, faced a common enterprise bottleneck: a diverse ecosystem of tools leading to inconsistent, error-prone deployments and complicated collaboration tha…
https://www.linkedin.com/posts/github-enterprise_how-astraze…

travel_explore

web search NEUTRAL — AstraZeneca and Ionis’ failure “simplifies the ATTR-CM landscape,” Mizuho Securities wrote in a Thursday note focused on BridgeBio. The biotech owns the TTR stabilizer Attruby, approved in November 20…
https://www.biospace.com/drug-development/astrazeneca-ionis-…

travel_explore

web search NEUTRAL — Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and develop…
https://www.genengnews.com/topics/artificial-intelligence/de…

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.